

Ming-Hua Zheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9567375/publications.pdf>

Version: 2024-02-01

302
papers

12,996
citations

31902

53
h-index

33814

99
g-index

311
all docs

311
docs citations

311
times ranked

14819
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 212-226.	0.7	4
2	Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. <i>British Journal of Nutrition</i> , 2022, 127, 1613-1620.	1.2	8
3	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1456-e1468.	2.4	49
4	Interaction of <i>SAMM50-rs738491</i> , <i>PARVB-rs5764455</i> and <i>PNPLA3-rs738409</i> Increases Susceptibility to Nonalcoholic Steatohepatitis. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 219-229.	0.7	3
5	A novel quantitative ultrasound technique for identifying non-alcoholic steatohepatitis. <i>Liver International</i> , 2022, 42, 80-91.	1.9	6
6	One not like the other: The weakness of the blood sugar-MAFLD analogy. <i>Journal of Hepatology</i> , 2022, 76, 482-484.	1.8	1
7	<i>PNPLA3</i> rs738409 C>G Variant Influences the Association Between Visceral Fat and Significant Fibrosis in Biopsy-proven Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 439-448.	0.7	1
8	Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. <i>Metabolism: Clinical and Experimental</i> , 2022, 126, 154911.	1.5	31
9	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
10	Protective association of <i>Klotho</i> rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 183-195.	4.5	6
11	Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 230-237.	0.7	15
12	Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. <i>Metabolism: Clinical and Experimental</i> , 2022, 128, 154958.	1.5	18
13	Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link?. <i>Liver International</i> , 2022, 42, 1496-1502.	1.9	25
14	Association of metabolic dysfunction-associated fatty liver disease with kidney disease. <i>Nature Reviews Nephrology</i> , 2022, 18, 259-268.	4.1	72
15	Derivation and validation of the nonalcoholic fatty liver disease cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis. <i>European Journal of Internal Medicine</i> , 2022, 98, 53-60.	1.0	4
16	J-shaped relationship between serum zinc levels and the severity of hepatic necro-inflammation in patients with MAFLD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1259-1265.	1.1	6
17	FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis. <i>Hepatology</i> , 2022, 76, 1105-1120.	3.6	23
18	The NAFLD^{MAFLD} debate: Is there a Consensus^{Consensus} methodology?. <i>Liver International</i> , 2022, 42, 742-748.	1.9	15

#	ARTICLE	IF	CITATIONS
19	Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 725-738.	4.5	10
20	Glycemic control predicts the risk of hepatic fibrosis in biopsy-proven NAFLD: a possible mediating role for leukemia inhibitory factor?. , 2022, 1, 30-34.		2
21	Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2022, 9, 864570.	1.2	5
22	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	1.8	114
23	Global multi-stakeholder endorsement of the MAFLD definition. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 388-390.	3.7	135
24	Effect of liver steatosis on liver stiffness measurement in chronic hepatitis B patients with normal serum alanine aminotransferase levels: A multicentre cohort study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 196-204.	1.0	1
25	Leukemia inhibitory factor protects against liver steatosis in nonalcoholic fatty liver disease patients and obese mice. <i>Journal of Biological Chemistry</i> , 2022, 298, 101946.	1.6	7
26	Hepatocellular cystathionine β lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor. <i>Hepatology</i> , 2022, 76, 1794-1810.	3.6	24
27	Nonalcoholic Fatty Liver Disease: Current Global Burden. <i>Seminars in Liver Disease</i> , 2022, 42, 401-412.	1.8	17
28	Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 391-401.	1.8	9
29	Lower serum copper concentrations are associated with higher prevalence of nonalcoholic steatohepatitis: a matched case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 838-843.	0.8	3
30	Promotion of nonalcoholic steatohepatitis by RNA N6-methyladenosine reader IGF2BP2 in mice. , 2022, 1, 161-174.		2
31	Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives. , 2022, 1, 57-65.		7
32	Promoting the term MAFLD: China in action. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 598.	3.7	13
33	Machine learning algorithms based on proteomic data mining accurately predicting the recurrence of hepatitis B-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 2145-2153.	1.4	7
34	Low skeletal muscle mass is associated with more severe histological features of non-alcoholic fatty liver disease in male. <i>Hepatology International</i> , 2022, 16, 1085-1093.	1.9	6
35	<i>FNDC5</i> polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease. <i>British Journal of Nutrition</i> , 2021, 126, 813-824.	1.2	11
36	Activating Adenosine Monophosphate-Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice. <i>Hepatology</i> , 2021, 73, 2206-2222.	3.6	43

#	ARTICLE	IF	CITATIONS
37	Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study. <i>Gut</i> , 2021, 70, gutjnl-2020-321666.	6.1	80
38	N6â€Methyladenosine Reader Protein YT521â€B Homology Domainâ€Containing 2 Suppresses Liver Steatosis by Regulation of mRNA Stability of Lipogenic Genes. <i>Hepatology</i> , 2021, 73, 91-103.	3.6	128
39	Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 204-207.	1.4	91
40	Extrapulmonary complications of COVIDâ€19: A multisystem disease?. <i>Journal of Medical Virology</i> , 2021, 93, 323-335.	2.5	131
41	Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. <i>Journal of Hepatology</i> , 2021, 74, 567-577.	1.8	377
42	Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 552-560.	1.1	7
43	MAFLD and risk of CKD. <i>Metabolism: Clinical and Experimental</i> , 2021, 115, 154433.	1.5	178
44	External Validation of the Nonalcoholic Steatohepatitis Scoring System in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease in China. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 412-413.	2.4	1
45	Myeloidâ€Cellâ€Specific ILâ€6 Signaling Promotes MicroRNAâ€223â€Enriched Exosome Production to Attenuate NAFLDâ€Associated Fibrosis. <i>Hepatology</i> , 2021, 74, 116-132.	3.6	99
46	Non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 9-10.	3.7	6
47	Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	5
48	Recommendations and Clinical Guidance for Children with Metabolic-associated Liver Disease during the COVID-19 Pandemic. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	2
49	Severe Acute Respiratory Syndrome Coronavirusâ€2 Infection in Children With Liver Transplant and Native Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 72, 807-814.	0.9	27
50	Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019. <i>Frontiers in Endocrinology</i> , 2021, 12, 604100.	1.5	25
51	Telomerase: a key player in the pathogenesis of non-alcoholic fatty liver disease?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 811-819.	1.4	3
52	Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00321.	1.3	6
53	Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 329-345.	4.5	14
54	The S100 calcium-binding protein A11 promotes hepatic steatosis through RAGE-mediated AKT-mTOR signaling. <i>Metabolism: Clinical and Experimental</i> , 2021, 117, 154725.	1.5	14

#	ARTICLE	IF	CITATIONS
55	Clinical utility of the MAFLD definition. <i>Journal of Hepatology</i> , 2021, 74, 989-991.	1.8	48
56	TA allele of rs2070673 in the <i>CYP2E1</i> gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2925-2934.	1.4	6
57	Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 593-603.	1.4	19
58	Spironolactone Improves the All-Cause Mortality and Re-Hospitalization Rates in Acute Myocardial Infarction with Chronic Kidney Disease Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 632978.	1.6	4
59	LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 452-459.	0.6	14
60	Consensus scoring systems for nonalcoholic fatty liver disease: an unmet clinical need. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 388-390.	0.7	16
61	Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 470-480.	1.9	19
62	The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1822-1831.	1.1	8
63	Editorial: an elastography-based two-step approach to detect NAFLD with compensated advanced chronic liver disease" authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 517-518.	1.9	0
64	Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study. <i>Journal of Hepatology</i> , 2021, 75, 439-441.	1.8	82
65	Letter: Hepatitis B and MAFLD – a consilience of risk factors for hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 736-737.	1.9	1
66	Histological Characteristics of Non-alcoholic Steatohepatitis in NAFLD Patients With Low Degree of Hepatocyte Apoptosis. , 2021, 32, 758-764.		0
67	acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. <i>EClinicalMedicine</i> , 2021, 41, 101145.	3.2	14
68	Fecal Fungi Dysbiosis in Nonalcoholic Fatty Liver Disease. <i>Obesity</i> , 2021, 29, 350-358.	1.5	13
69	Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 430-435.	0.8	12
70	Radiomics based on fluoro-deoxyglucose positron emission tomography predicts liver fibrosis in biopsy-proven MAFLD: a pilot study. <i>International Journal of Medical Sciences</i> , 2021, 18, 3624-3630.	1.1	4
71	Entwicklung und Validierung des NAFLD Cirrhosis Score (NCS) zur Separierung von fortgeschrittener Fibrose und Zirrhose. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.2	0
72	Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	38

#	ARTICLE	IF	CITATIONS
73	Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study. <i>Hepatology International</i> , 2021, 15, 1337-1346.	1.9	15
74	Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 849-852.	0.7	12
75	Metabolic-associated Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	1
76	The uprising of metabolic dysfunction-associated fatty liver disease (MAFLD) in acute-on-chronic liver failure (ACLF). <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 857-859.	0.7	7
77	Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. <i>Chinese Medical Journal</i> , 2021, 134, 2911-2921.	0.9	21
78	Association between non-alcoholic fatty liver disease and myocardial glucose uptake measured by 18F-fluorodeoxyglucose positron emission tomography. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 1679-1688.	1.4	6
79	Development and Validation of Hepamet Fibrosis Scoring System—A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	2.4	104
80	Effect of <i>PNPLA3</i> polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1057-1064.	1.4	27
81	<i>PNPLA3</i> rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. <i>Liver International</i> , 2020, 40, 107-119.	1.9	67
82	Homeostatic model assessment of insulin resistance closely related to lobular inflammation in nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 80-86.	0.8	7
83	Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD. <i>Diabetes and Metabolism</i> , 2020, 46, 288-295.	1.4	24
84	From NAFLD to MAFLD: a "redefining" moment for fatty liver disease. <i>Chinese Medical Journal</i> , 2020, 133, 2271-2273.	0.9	79
85	COVID-19 Cross-Infection and Pressured Ulceration Among Healthcare Workers: Are We Really Protected by Respirators?. <i>Frontiers in Medicine</i> , 2020, 7, 571493.	1.2	4
86	Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 1571-1573.	1.8	18
87	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <i>Hepatology International</i> , 2020, 14, 889-919.	1.9	422
88	Non-invasive fibrosis assessment in non-alcoholic fatty liver disease. <i>Chinese Medical Journal</i> , 2020, 133, 2743-2745.	0.9	7
89	Abnormal liver enzymes in children and infants with COVID-19: A narrative review of case-series studies. <i>Pediatric Obesity</i> , 2020, 15, e12723.	1.4	18
90	Data sharing during COVID-19 pandemic: what to take away. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 1125-1130.	1.4	20

#	ARTICLE	IF	CITATIONS
91	Radiomics-based model for accurately distinguishing between severe acute respiratory syndrome associated coronavirus 2 (SARS-CoV-2) and influenza A infected pneumonia. <i>MedComm</i> , 2020, 1, 240-248.	3.1	16
92	ACE2: A Linkage for the Interplay Between COVID-19 and Decompensated Cirrhosis. <i>American Journal of Gastroenterology</i> , 2020, 115, 1544-1544.	0.2	14
93	When a new definition overhauls perceptions of MAFLD related cirrhosis care. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 801-804.	0.7	22
94	Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis. <i>Journal of Hepatology</i> , 2020, 73, 719-721.	1.8	112
95	Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. <i>Gut</i> , 2020, 69, 1545-1547.	6.1	166
96	Association between NAFLD and risk of prevalent chronic kidney disease: why there is a difference between east and west?. <i>BMC Gastroenterology</i> , 2020, 20, 139.	0.8	23
97	Patients with diabetes are at higher risk for severe illness from COVID-19. <i>Diabetes and Metabolism</i> , 2020, 46, 335-337.	1.4	124
98	Obesity Is a Risk Factor for Greater COVID-19 Severity. <i>Diabetes Care</i> , 2020, 43, e72-e74.	4.3	323
99	Subclinical Acute Kidney Injury in COVID-19 Patients: A Retrospective Cohort Study. <i>Nephron</i> , 2020, 144, 347-350.	0.9	21
100	COVID-19 and liver transplantation: Lessons learned from three reported cases. <i>Transplant Infectious Disease</i> , 2020, 22, e13335.	0.7	20
101	Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1236-1248.	1.1	196
102	Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. <i>Diabetes and Metabolism</i> , 2020, 46, 505-507.	1.4	34
103	COVID-19 in a patient with chronic lymphocytic leukaemia. <i>Lancet Haematology</i> , the, 2020, 7, e351-e352.	2.2	66
104	Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2041-2050.	1.4	67
105	Metabolic-associated fatty liver disease is associated with severity of COVID-19. <i>Liver International</i> , 2020, 40, 2160-2163.	1.9	80
106	Lower levels of plasma NT-proBNP are associated with higher prevalence of NASH in patients with biopsy-proven NAFLD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1820-1825.	1.1	9
107	Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). <i>Hepatology International</i> , 2020, 14, 690-700.	1.9	210
108	PNPLA3 polymorphism influences the association between high-normal TSH level and NASH in euthyroid adults with biopsy-proven NAFLD. <i>Diabetes and Metabolism</i> , 2020, 46, 496-503.	1.4	5

#	ARTICLE	IF	CITATIONS
109	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 362-373.	3.7	411
110	Fatal outcome in a liver transplant recipient with COVID-19. <i>American Journal of Transplantation</i> , 2020, 20, 1907-1910.	2.6	77
111	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	1.8	2,171
112	Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1804-1812.	1.4	15
113	Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001174.	1.2	21
114	Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 108, 154244.	1.5	281
115	Letter to the Editor: Obesity hypoventilation syndrome and severe COVID-19. <i>Metabolism: Clinical and Experimental</i> , 2020, 108, 154249.	1.5	25
116	A Case Series of Recurrent Viral RNA Positivity in Recovered COVID-19 Chinese Patients. <i>Journal of General Internal Medicine</i> , 2020, 35, 2205-2206.	1.3	47
117	Development and Validation of a Radiomic-Based Model for Prediction of Intrahepatic Cholangiocarcinoma in Patients With Intrahepatic Lithiasis Complicated by Imagologically Diagnosed Mass. <i>Frontiers in Oncology</i> , 2020, 10, 598253.	1.3	12
118	COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-7.	0.7	329
119	Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram. <i>United European Gastroenterology Journal</i> , 2019, 7, 1124-1134.	1.6	29
120	Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis. <i>Obesity</i> , 2019, 27, 2055-2066.	1.5	22
121	Fatty Liver Disease Caused by High-Alcohol-Producing <i>Klebsiella pneumoniae</i> . <i>Cell Metabolism</i> , 2019, 30, 675-688.e7.	7.2	294
122	Prognostic value of hematocrit levels among critically ill patients with acute kidney injury. <i>European Journal of Inflammation</i> , 2019, 17, 205873921984682.	0.2	1
123	PS-201-External validation in NAFLD cohorts of the FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST to identify patients with active NASH (NAS \geq 4) and significant fibrosis (F \geq 2). <i>Journal of Hepatology</i> , 2019, 70, e134-e135.	1.8	1
124	SAT-336-Liver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 70, e787.	1.8	0
125	A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease. <i>Clinical Nutrition</i> , 2019, 38, 2552-2557.	2.3	49
126	A simpler diagnostic formula for screening nonalcoholic fatty liver disease. <i>Clinical Biochemistry</i> , 2019, 64, 18-23.	0.8	9

#	ARTICLE	IF	CITATIONS
127	Metabolic Acidosis in Critically Ill Cirrhotic Patients with Acute Kidney Injury. <i>Journal of Clinical and Translational Hepatology</i> , 2019, 7, 1-10.	0.7	5
128	A Novel Use of Model for End-Stage Liver Disease (MELD) Score in Guiding Therapeutic Antibiotics Choice for Critically Ill Cirrhotic Patients. <i>Medical Science Monitor</i> , 2019, 25, 5005-5014.	0.5	0
129	Perceptions of Chinese Biomedical Researchers Towards Academic Misconduct: A Comparison Between 2015 and 2010. <i>Science and Engineering Ethics</i> , 2018, 24, 629-645.	1.7	30
130	Wet beriberi with multiple organ failure remarkably reversed by thiamine administration. <i>Medicine (United States)</i> , 2018, 97, e0010.	0.4	38
131	Lifestyle interventions for patients with nonalcoholic fatty liver disease: a network meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 747-755.	0.8	40
132	Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis. <i>Hepatology Communications</i> , 2018, 2, 376-392.	2.0	91
133	High fiber dietary and sodium butyrate attenuate experimental autoimmune hepatitis through regulation of immune regulatory cells and intestinal barrier. <i>Cellular Immunology</i> , 2018, 328, 24-32.	1.4	67
134	Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. <i>Advances in Therapy</i> , 2018, 35, 218-231.	1.3	13
135	Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 631-636.	0.8	78
136	Stratified alpha-fetoprotein pattern accurately predicts mortality in patients with acute-on-chronic hepatitis B liver failure. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 295-302.	1.4	5
137	BMSCs-derived miR-223-containing exosomes contribute to liver protection in experimental autoimmune hepatitis. <i>Molecular Immunology</i> , 2018, 93, 38-46.	1.0	169
138	Serum lactate level accurately predicts mortality in critically ill patients with cirrhosis with acute kidney injury. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1361-1367.	0.8	19
139	MetS Risk Score: A Clear Scoring Model to Predict a 3-Year Risk for Metabolic Syndrome. <i>Hormone and Metabolic Research</i> , 2018, 50, 683-689.	0.7	14
140	Thrombin generation and platelet activation in cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy - A prospective cohort study. <i>PLoS ONE</i> , 2018, 13, e0193657.	1.1	12
141	Sarcopenia Contributes to the Progression of Nonalcoholic Fatty Liver Disease- Related Fibrosis: A Meta-Analysis. <i>Digestive Diseases</i> , 2018, 36, 427-436.	0.8	43
142	Hepatic resection for elderly patients with hepatocellular carcinoma: a systematic review of more than 17,000 patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1059-1068.	1.4	19
143	Serum alkaline phosphatase, a risk factor for non-alcoholic fatty liver, but only for women in their 30s and 40s: evidence from a large cohort study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 1-8.	1.4	9
144	The NAFL Risk Score: A simple scoring model to predict 4-y risk for non-alcoholic fatty liver. <i>Clinica Chimica Acta</i> , 2017, 468, 17-24.	0.5	8

#	ARTICLE	IF	CITATIONS
145	Abnormality in a fetus on ultrasound. <i>BMJ: British Medical Journal</i> , 2017, 356, j688.	2.4	0
146	Quick chronic liver failure-sequential organ failure assessment. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 698-705.	0.8	7
147	Immunosuppressive Agents for the Treatment of Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis. <i>Digestive Diseases</i> , 2017, 35, 478-485.	0.8	18
148	A painful wrist after a fall. <i>BMJ: British Medical Journal</i> , 2017, 357, j1642.	2.4	0
149	Acute circulatory failureâ€“chronic liver failureâ€“sequential organ failure assessment score: a novel scoring model for mortality risk prediction in critically ill cirrhotic patients with acute circulatory failure. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 464-471.	0.8	3
150	Scoring model to predict outcome in critically ill cirrhotic patients with acute respiratory failure: comparison with MELD scoring models and CLIF-SOFA score. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 857-864.	1.4	3
151	C-reactive protein-to-albumin ratio is a predictor of hepatitis B virus related decompensated cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 472-480.	0.8	18
152	Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 503-513.	2.0	17
153	NAFL screening score: A basic score identifying ultrasound-diagnosed non-alcoholic fatty liver. <i>Clinica Chimica Acta</i> , 2017, 475, 44-50.	0.5	12
154	Elevation of plateletcrit increasing the risk of non-alcoholic fatty liver disease development in female adults: A large population-based study. <i>Clinica Chimica Acta</i> , 2017, 474, 28-33.	0.5	5
155	Comparative efficacy of vasoconstrictor therapies for type 1 hepatorenal syndrome: a network meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 1009-1018.	1.4	15
156	Development of a prognostic nomogram for cirrhotic patients with upper gastrointestinal bleeding. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1166-1173.	0.8	11
157	Sodium butyrate ameliorates S100/FCA-induced autoimmune hepatitis through regulation of intestinal tight junction and toll-like receptor 4 signaling pathway. <i>Immunology Letters</i> , 2017, 190, 169-176.	1.1	28
158	Remodeling the model for endâ€“stage liver disease for predicting mortality risk in critically ill patients with cirrhosis and acute kidney injury. <i>Hepatology Communications</i> , 2017, 1, 748-756.	2.0	4
159	Association between oxytocin and receptor genetic polymorphisms and aggression in a northern Chinese Han population with alcohol dependence. <i>Neuroscience Letters</i> , 2017, 636, 140-144.	1.0	13
160	Usefulness of albuminâ€“bilirubin grade for evaluation of longâ€“term prognosis for hepatitis Bâ€“related cirrhosis. <i>Journal of Viral Hepatitis</i> , 2017, 24, 238-245.	1.0	68
161	Classification and regression tree analysis of acuteâ€“onâ€“chronic hepatitis B liver failure: Seeing the forest for the trees. <i>Journal of Viral Hepatitis</i> , 2017, 24, 132-140.	1.0	18
162	AKI-CLIF-SOFA: a novel prognostic score for critically ill cirrhotic patients with acute kidney injury. <i>Aging</i> , 2017, 9, 286-296.	1.4	11

#	ARTICLE	IF	CITATIONS
163	Impact of platelet to lymphocyte ratio and metabolic syndrome on the prognosis of colorectal cancer patients. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2199-2208.	1.0	19
164	Prognostic value of platelet-to-lymphocyte ratios among critically ill patients with acute kidney injury. <i>Critical Care</i> , 2017, 21, 238.	2.5	71
165	Stratified Platelet-to-lymphocyte Ratio: A Novel Target for Prognostic Prediction of Hepatocellular Carcinoma after Curative Liver Resection. <i>Journal of Clinical and Translational Hepatology</i> , 2017, XX, 1-8.	0.7	5
166	Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching. <i>Oncotarget</i> , 2017, 8, 51810-51816.	0.8	6
167	Is laparoscopic hepatectomy superior to open hepatectomy for hepatocellular carcinoma?. <i>World Journal of Hepatology</i> , 2017, 9, 167.	0.8	4
168	Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 21753-21762.	0.8	68
169	Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. <i>Oncotarget</i> , 2016, 7, 30642-30658.	0.8	57
170	Emerging Role of Interleukin 22 in Hepatitis B Virus Infection: a Double-edged Sword. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 1, 103-8.	0.7	11
171	Establishment and Validation of GV-SAPS II Scoring System for Non-Diabetic Critically Ill Patients. <i>PLoS ONE</i> , 2016, 11, e0166085.	1.1	11
172	Nasal NK/T cell lymphoma presents with long-term nasal blockage and fever: a rare case report and literature review. <i>Oncotarget</i> , 2016, 7, 9613-9617.	0.8	4
173	Methimazole-induced cholestatic hepatitis: two cases report and literature review. <i>Oncotarget</i> , 2016, 7, 5088-5091.	0.8	17
174	Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Medicine (United States)</i> , 2016, 95, e2596.	0.4	23
175	A boy with a sac-like protrusion at the occipital region. <i>BMJ, The</i> , 2016, 353, i2073.	3.0	0
176	Platelet-to-Lymphocyte Ratio. <i>Medicine (United States)</i> , 2016, 95, e2596.	0.4	23
177	Association of low-density lipoprotein cholesterol within the normal range and NAFLD in the non-obese Chinese population: a cross-sectional and longitudinal study. <i>BMJ Open</i> , 2016, 6, e013781.	0.8	48
178	A girl with left wrist deformity. <i>BMJ, The</i> , 2016, 355, i4925.	3.0	0
179	Targeting endoplasmic reticulum stress in liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1041-1052.	1.4	34
180	A neonate with dyspnoea. <i>BMJ, The</i> , 2016, 353, i2361.	3.0	0

#	ARTICLE	IF	CITATIONS
181	A young man with recurrent limb shaking. <i>BMJ, The</i> , 2016, 354, i4502.	3.0	0
182	Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 979-987.	2.0	15
183	Association between age and overall survival of patients with hepatocellular carcinoma after hepatic resection. <i>Journal of Surgical Oncology</i> , 2016, 114, 966-970.	0.8	16
184	A girl with an abnormal gait. <i>BMJ, The</i> , 2016, 355, i5216.	3.0	0
185	Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury. <i>Scientific Reports</i> , 2016, 6, 31026.	1.6	58
186	Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2016, 6, 33743.	1.6	61
187	Normalization methods in time series of platelet function assays. <i>Medicine (United States)</i> , 2016, 95, e4188.	0.4	3
188	Successful Treatment of Scrub Typhus-Associated Hemophagocytic Lymphohistiocytosis With Chloramphenicol. <i>Medicine (United States)</i> , 2016, 95, e2928.	0.4	6
189	Toll-like receptors in hepatocellular carcinoma: potential novel targets for pharmacological intervention. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 1127-1135.	1.5	13
190	The role of lncRNAs in hepatocellular carcinoma: opportunities as novel targets for pharmacological intervention. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 331-340.	1.4	18
191	Kidney bioengineering in regenerative medicine: An emerging therapy for kidney disease. <i>Cytotherapy</i> , 2016, 18, 186-197.	0.3	17
192	Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 375-387.	1.5	22
193	National incidence of autoimmune liver diseases and its relationship with the human development index. <i>Oncotarget</i> , 2016, 7, 46273-46282.	0.8	10
194	Is an elevated hemoglobin concentration a novel risk factor for metabolic syndrome in the Chinese population? a large-scale study. <i>Oncotarget</i> , 2016, .	0.8	2
195	Stratified neutrophil-to-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection. <i>Oncotarget</i> , 2016, 7, 5429-5439.	0.8	17
196	Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease. <i>Oncotarget</i> , 2016, 7, 5728-5737.	0.8	37
197	Parabolic relationship between sex-specific serum high sensitive C reactive protein and non-alcoholic fatty liver disease in chinese adults: a large population-based study. <i>Oncotarget</i> , 2016, 7, 14241-14250.	0.8	6
198	Preoperative platelet to lymphocyte ratio is a valuable prognostic biomarker in patients with colorectal cancer. <i>Oncotarget</i> , 2016, 7, 25516-25527.	0.8	52

#	ARTICLE	IF	CITATIONS
199	Increased Levels of Systolic Blood Pressure Within the Normal Range Are Associated With Significantly Elevated Risks of Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2015, 94, e842.	0.4	32
200	Long-term Pegylated Interferon- α -2a Treatment for Chronic Hepatitis C in an Elderly Renal Transplant Recipient. <i>Medicine (United States)</i> , 2015, 94, e390.	0.4	3
201	Cerebral hemorrhage due to tuberculosis meningitis: a rare case report and literature review. <i>Oncotarget</i> , 2015, 6, 45005-45009.	0.8	14
202	Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis. <i>Oncotarget</i> , 2015, 6, 18151-18161.	0.8	39
203	Establishment and Validation of SSCLIP Scoring System to Estimate Survival in Hepatocellular Carcinoma Patients Who Received Curative Liver Resection. <i>PLoS ONE</i> , 2015, 10, e0129000.	1.1	15
204	Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance. <i>Oncotarget</i> , 2015, 6, 25093-25108.	0.8	99
205	Recent advances in re-engineered liver: de-cellularization and re-cellularization techniques. <i>Cytotherapy</i> , 2015, 17, 1015-1024.	0.3	5
206	Axial computed tomogram of the glottis. <i>BMJ, The</i> , 2015, 350, h11-h11.	3.0	1
207	Anteroposterior radiograph of a barium examination of the oesophagus. <i>BMJ, The</i> , 2015, 350, h1169-h1169.	3.0	0
208	Axial contrast enhanced computed tomogram of the lower neck. <i>BMJ, The</i> , 2015, 350, h648-h648.	3.0	0
209	Anteroposterior radiograph of the right shoulder. <i>BMJ, The</i> , 2015, 350, h901-h901.	3.0	0
210	Establishment and Validation of ALPH-Q Score to Predict Mortality Risk in Patients With Acute-on-Chronic Hepatitis B Liver Failure. <i>Medicine (United States)</i> , 2015, 94, e403.	0.4	19
211	Association Between Sex-Specific Serum Uric Acid and Non-Alcoholic Fatty Liver Disease in Chinese Adults. <i>Medicine (United States)</i> , 2015, 94, e802.	0.4	50
212	Combined AFP-CRUT with microvascular invasion accurately predicts mortality risk in patients with hepatocellular carcinoma following curative liver resection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1127-1138.	1.4	2
213	Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 675-685.	1.5	28
214	Axial T2 weighted magnetic resonance image of the heart. <i>BMJ, The</i> , 2015, 350, h196-h196.	3.0	0
215	Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 624-635.	1.9	75
216	Anteroposterior radiograph of a barium examination of the stomach. <i>BMJ, The</i> , 2015, 350, h1311-h1311.	3.0	0

#	ARTICLE	IF	CITATIONS
217	Sagittal T2 weighted magnetic resonance image of the female pelvis. <i>BMJ, The</i> , 2015, 350, h1611-h1611.	3.0	0
218	Computed tomography angiogram of the thoracic vessels. <i>BMJ, The</i> , 2015, 350, h1782-h1782.	3.0	0
219	Axial computed tomogram of the nasopharynx. <i>BMJ, The</i> , 2015, 350, h1921-h1921.	3.0	0
220	Decellularization technology in CNS tissue repair. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 493-500.	1.4	19
221	Anteroposterior radiograph of the elbow joint. <i>BMJ, The</i> , 2015, 350, h2243-h2243.	3.0	0
222	Network Meta-Analysis of Randomized Controlled Trials. <i>Medicine (United States)</i> , 2015, 94, e609.	0.4	17
223	Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2015, 94, e479.	0.4	21
224	Systematic Review With Network Meta-Analysis. <i>Medicine (United States)</i> , 2015, 94, e379.	0.4	9
225	New advances in liver decellularization and recellularization: innovative and critical technologies. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1183-1191.	1.4	8
226	High resolution axial computed tomogram of the ear. <i>BMJ, The</i> , 2015, 350, h2048-h2048.	3.0	0
227	Autophagy in ethanol-exposed liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1031-1037.	1.4	8
228	Skin lesion in a critically ill man. <i>BMJ, The</i> , 2015, 351, h4570.	3.0	3
229	Increased delayed mortality in patients with acute-on-chronic liver failure who have prior decompensation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 712-718.	1.4	35
230	Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer. <i>Oncotarget</i> , 2015, 6, 19880-19890.	0.8	43
231	Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis. <i>Oncotarget</i> , 2015, 6, 24533-24549.	0.8	10
232	Conditional survival estimate of acute-on-chronic hepatitis B liver failure: A dynamic prediction based on a multicenter cohort. <i>Oncotarget</i> , 2015, 6, 23261-23271.	0.8	12
233	A network meta-analysis of the efficacy and side effects of udca-based therapies for primary sclerosing cholangitis. <i>Oncotarget</i> , 2015, 6, 26757-26769.	0.8	22
234	Massive cardiac tamponade. <i>BMJ, The</i> , 2014, 348, g3707-g3707.	3.0	0

#	ARTICLE	IF	CITATIONS
235	The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1305-1313.	1.5	22
236	Scoring systems predict the prognosis of acute-on-chronic hepatitis B liver failure: an evidence-based review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 623-632.	1.4	14
237	Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 759-770.	1.9	28
238	Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. <i>Molecular Biology Reports</i> , 2014, 41, 2989-2997.	1.0	58
239	Non-alcoholic fatty liver disease and risk of in-stent restenosis after bare metal stenting in native coronary arteries. <i>Molecular Biology Reports</i> , 2014, 41, 4713-4720.	1.0	9
240	ApoE-Deficient Promotes Blood-Brain Barrier Disruption in Experimental Autoimmune Encephalomyelitis via Alteration of MMP-9. <i>Journal of Molecular Neuroscience</i> , 2014, 54, 282-290.	1.1	26
241	Factors associated with efficacy of pegylated interferon- α plus ribavirin for chronic hepatitis C after renal transplantation. <i>Gene</i> , 2014, 544, 101-106.	1.0	3
242	Three dimensional reconstruction of a CT angiogram of the left upper arm vessels. <i>BMJ, The</i> , 2014, 348, g3949-g3949.	3.0	1
243	Axial T2 weighted magnetic resonance imaging of the male pelvis. <i>BMJ, The</i> , 2014, 349, g4910-g4910.	3.0	0
244	Artificial Neural Network Accurately Predicts Hepatitis B Surface Antigen Seroclearance. <i>PLoS ONE</i> , 2014, 9, e99422.	1.1	9
245	Axial T2 weighted magnetic resonance image of the base of the brain. <i>BMJ, The</i> , 2014, 349, g4445-g4445.	3.0	0
246	A New Strategy for Treatment of Liver Fibrosis. <i>BioDrugs</i> , 2013, 27, 25-34.	2.2	30
247	Disparate profiles of dys-regulated miRNAs in activated hepatic stellate cells. <i>Hepatology</i> , 2013, 57, 1285-1286.	3.6	6
248	Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. <i>Liver International</i> , 2013, 33, 62-71.	1.9	173
249	A model to predict 3-month mortality risk of acute-on-chronic hepatitis B liver failure using artificial neural network. <i>Journal of Viral Hepatitis</i> , 2013, 20, 248-255.	1.0	40
250	Interleukin-28B rs12979860C/T and rs8099917T/G contribute to spontaneous clearance of hepatitis C virus in Caucasians. <i>Gene</i> , 2013, 518, 479-482.	1.0	16
251	Secondary prophylaxis of variceal bleeding for cirrhotic patients: a multiple-treatments meta-analysis. <i>European Journal of Clinical Investigation</i> , 2013, 43, 844-854.	1.7	21
252	Oral Acetyl-L-Carnitine treatment in hepatic encephalopathy: view of evidence-based medicine. <i>Annals of Hepatology</i> , 2013, 12, 803-809.	0.6	33

#	ARTICLE	IF	CITATIONS
253	Invasive fungal infection in patients with systemic lupus erythematosus: Experience from a single institute of Northern China. <i>Gene</i> , 2012, 506, 184-187.	1.0	16
254	Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon- α plus ribavirin: A meta-analysis. <i>Gene</i> , 2012, 507, 27-35.	1.0	15
255	Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>Molecular Biology Reports</i> , 2012, 39, 9715-9722.	1.0	76
256	Risk stratification of spontaneous bacterial peritonitis in cirrhosis with ascites based on classification and regression tree analysis. <i>Molecular Biology Reports</i> , 2012, 39, 6161-6169.	1.0	16
257	The tumour necrosis factor- α -238A allele increases the risk of chronic HBV infection in European populations. <i>Journal of Viral Hepatitis</i> , 2012, 19, e11-7.	1.0	27
258	Tumour necrosis factor- α -857T allele reduces the risk of hepatitis B virus infection in an Asian population. <i>Journal of Viral Hepatitis</i> , 2012, 19, e66-72.	1.0	24
259	Upper Limits of Normal for Serum Alanine Aminotransferase Levels in Chinese Han Population. <i>PLoS ONE</i> , 2012, 7, e43736.	1.1	28
260	A Model to Determine 3-Month Mortality Risk in Patients With Acute-on-Chronic Hepatitis B Liver Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 351-356.e3.	2.4	64
261	T-helper 17 cell: A distinctive cell in liver diseases. <i>Hepatology Research</i> , 2011, 41, 22-29.	1.8	21
262	OL-084 Tumor necrosis factor- α -857T allele reduces the risk of chronic HBV infection in Asian population. <i>International Journal of Infectious Diseases</i> , 2011, 15, S44.	1.5	0
263	Methodological quality assessment for traditional Chinese medicine: CONSORT is better. <i>Hepatology</i> , 2011, 53, 2148-2149.	3.6	5
264	Meta-analysis using individual participant data is the gold standard for diagnostic studies. <i>Hepatology</i> , 2011, 53, 1062-1063.	3.6	3
265	Nucleoside Analogue Can Improve the Long-Term Prognosis of Patients with Hepatitis B Virus Infection-Associated Acute on Chronic Liver Failure. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2373-2380.	1.1	89
266	A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. <i>Clinical Therapeutics</i> , 2010, 32, 649-658.	1.1	21
267	Liver tissue engineering: promises and prospects of new technology. <i>Cytotherapy</i> , 2010, 12, 349-360.	0.3	13
268	Peroxisome proliferator-activated receptor- γ (PPAR- γ) agonist inhibits transforming growth factor-beta1 and matrix production in human dermal fibroblasts. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2010, 63, 1209-1216.	0.5	27
269	Multifocal skeletal tuberculosis: Experience in diagnosis and treatment. <i>Médecine Et Maladies Infectieuses</i> , 2010, 40, 6-11.	5.1	32
270	Tumor necrosis factor- α -308A allele may have a protective effect for chronic hepatitis B virus infection in Mongoloid populations. <i>International Journal of Infectious Diseases</i> , 2010, 14, e580-e585.	1.5	22

#	ARTICLE	IF	CITATIONS
271	The Quality of Randomized Controlled Trials on DanShen in the Treatment of Ischemic Vascular Disease. <i>Journal of Alternative and Complementary Medicine</i> , 2009, 15, 557-565.	2.1	15
272	FAS $\hat{1}$,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls. <i>Human Genetics</i> , 2009, 125, 431-435.	1.8	16
273	ATG16L1 T300A polymorphism and Crohn's disease susceptibility: evidence from 13,022 cases and 17,532 controls. <i>Human Genetics</i> , 2009, 125, 627-631.	1.8	63
274	Activation of peroxisome proliferator-activated receptor- $\hat{1}$ 3 inhibits transforming growth factor- $\hat{1}$ 21 induction of connective tissue growth factor and extracellular matrix in hypertrophic scar fibroblasts in vitro. <i>Archives of Dermatological Research</i> , 2009, 301, 515-522.	1.1	24
275	Retrospective analysis of nosocomial infections in the intensive care unit of a tertiary hospital in China during 2003 and 2007. <i>BMC Infectious Diseases</i> , 2009, 9, 115.	1.3	47
276	More statistical analysis is needed for the meta-analysis of genetic association studies. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 143-144.	1.9	3
277	Prediction of the prognosis of patients with acute-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. <i>Journal of Viral Hepatitis</i> , 2009, 16, 464-470.	1.0	70
278	The E-cadherin (CDH1) $\hat{1}$ 60 C/A polymorphism and prostate cancer risk: a meta-analysis. <i>European Journal of Human Genetics</i> , 2009, 17, 244-249.	1.4	31
279	Ornithine aspartate in the management of hepatic encephalopathy: A meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 9-14.	1.4	70
280	Effectiveness and tolerability of NSAIDs in the prophylaxis of pancreatitis after endoscopic retrograde cholangiopancreatography: A systematic review and meta-analysis. <i>Current Therapeutic Research</i> , 2009, 70, 323-334.	0.5	6
281	MTHFR C677T polymorphism contributes to prostate cancer risk among Caucasians: A meta-analysis of 3511 cases and 2762 controls. <i>European Journal of Cancer</i> , 2009, 45, 1443-1449.	1.3	40
282	Aquaporin, a kind of membrane channel protein, maybe a new promising therapeutic target for non-alcoholic fatty liver disease. <i>Bioscience Hypotheses</i> , 2009, 2, 111-112.	0.2	0
283	Test for hepatitis B virus infection with radical immunoassay and real-time PCR: Which method is the gold standard?. <i>Journal of Hepatology</i> , 2009, 50, 211-212.	1.8	0
284	Mixed microencapsulation of rat primary hepatocytes and Sertoli cells improves the metabolic function in a D-galactosamine and lipopolysaccharide-induced rat model of acute liver failure. <i>Cytotherapy</i> , 2009, 11, 326-329.	0.3	13
285	Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis. <i>BMC Gastroenterology</i> , 2008, 8, 6.	0.8	43
286	Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: Evidence from 24 studies. <i>International Journal of Cancer</i> , 2008, 123, 2384-2389.	2.3	76
287	FEVER OF UNKNOWN ORIGIN IN ELDERLY PEOPLE: A RETROSPECTIVE STUDY OF 87 PATIENTS IN CHINA. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 182-184.	1.3	10
288	Omega-3 polyunsaturated fatty acids: A specific liver drug for non-alcoholic fatty liver disease (NAFLD). <i>Medical Hypotheses</i> , 2008, 71, 820-821.	0.8	15

#	ARTICLE	IF	CITATIONS
289	Effects of vasoactive intestinal peptide on phenotypic and functional maturation of dendritic cells. <i>International Immunopharmacology</i> , 2008, 8, 1449-1454.	1.7	12
290	Hepatitis B virus X protein disrupts DNA interstrand crosslinking agent mitomycin C induced ATR dependent intra-S-phase checkpoint. <i>European Journal of Cancer</i> , 2008, 44, 1596-1602.	1.3	12
291	Recombinant human hepatocyte growth factor for liver failure. <i>Contemporary Clinical Trials</i> , 2008, 29, 696-704.	0.8	16
292	Recombinant human hepatocyte growth factor for liver failure. <i>Contemporary Clinical Trials</i> , 2008, 29, 919.	0.8	0
293	Gabexate mesylate in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis update. <i>Current Therapeutic Research</i> , 2008, 69, 288-304.	0.5	11
294	Searching Additional Databases Except PubMed Are Necessary for a Systematic Review. <i>Stroke</i> , 2008, 39, e139; author reply e140.	1.0	10
295	Fever of unknown origin in the elderly: nine years experience in China. <i>Tropical Doctor</i> , 2008, 38, 221-222.	0.2	6
296	Traditional Chinese Medicine Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma. <i>Journal of Alternative and Complementary Medicine</i> , 2008, 14, 1027-1042.	2.1	30
297	Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Therapy in the Secondary Prophylaxis of Variceal Rebleeding in Cirrhotic Patients. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 507-516.	1.1	134
298	Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 1064-1070.	0.8	102
299	Meta-Analysis of Prophylactic Allopurinol Use in Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. <i>Pancreas</i> , 2008, 37, 247-253.	0.5	33
300	Association between the presence of H pylori in the liver and hepatocellular carcinoma: A meta-analysis. <i>World Journal of Gastroenterology</i> , 2008, 14, 307.	1.4	30
301	Interleukin-18: a pro-inflammatory cytokine that plays an important role in acute pancreatitis. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1261-1271.	1.5	23
302	Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. <i>BMC Gastroenterology</i> , 2007, 7, 6.	0.8	43